Drugs Made In America Acquisition (DMAA) Institutional Ownership $10.27 0.00 (0.00%) As of 08/22/2025 Add Compare Share Share Ownership Stock AnalysisChartCompetitorsOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Drugs Made In America Acquisition (NASDAQ:DMAA)Number ofInstitutional Buyers(last 12 months)7Number ofInstitutional Sellers(last 12 months)2 Get DMAA Insider Trade Alerts Want to know when executives and insiders are buying or selling Drugs Made In America Acquisition stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data DMAA Institutional Buying and Selling by Quarter Drugs Made In America Acquisition Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Radcliffe Capital Management L.P.126,722$1.29M0.1%N/A0.434% 8/15/2025 Boothbay Fund Management LLC570,000$5.81M0.1%N/A1.954% 8/15/2025 AQR Arbitrage LLC376,314$3.84M0.1%-1.1%1.290% 8/14/2025 Shaolin Capital Management LLC100,000$1.02M0.0%N/A0.343% 8/14/2025 Karpus Management Inc.2,744,109$27.99M0.9%+18.1%9.407% 8/13/2025 Clear Street LLC112,615$1.15M0.0%N/A0.386% 8/13/2025 DLD Asset Management LP188,722$1.93M0.0%-73.0%0.647% 8/4/2025 Wolverine Asset Management LLC1,021,906$10.42M0.1%+69.5%3.503% 8/1/2025Mizuho Securities USA LLC542,962$5.40M0.1%N/A1.861% (Data available from 1/1/2016 forward) DMAA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of DMAA shares? During the previous two years, 9 institutional investors and hedge funds held shares of Drugs Made In America Acquisition. The most heavily invested institutionals were Karpus Management Inc. ($27.99M), Wolverine Asset Management LLC ($10.42M), Boothbay Fund Management LLC ($5.81M), Mizuho Securities USA LLC ($5.40M), AQR Arbitrage LLC ($3.84M), DLD Asset Management LP ($1.93M), and Radcliffe Capital Management L.P. ($1.29M).Learn more on Drugs Made In America Acquisition's institutional investors. Which institutional investors have been buying Drugs Made In America Acquisition's stock? The following institutional investors have purchased Drugs Made In America Acquisition's stock in the last 24 months: Boothbay Fund Management LLC ($570K), Mizuho Securities USA LLC ($542.96K), Karpus Management Inc. ($420.08K), Wolverine Asset Management LLC ($418.87K), Radcliffe Capital Management L.P. ($126.72K), Clear Street LLC ($112.62K), and Shaolin Capital Management LLC ($100K). How much institutional buying is happening at Drugs Made In America Acquisition? Institutional investors have bought a total of 2,291,242 shares in the last 24 months. This purchase volume represents approximately $0.00 in transactions. Which of Drugs Made In America Acquisition's major shareholders have been selling company stock? The following institutional investors have sold Drugs Made In America Acquisition stock in the last 24 months: DLD Asset Management LP ($511.28K), and AQR Arbitrage LLC ($4K). How much institutional selling is happening at Drugs Made In America Acquisition? Institutional investors have sold a total of 515,278 shares in the last 24 months. This volume of shares sold represents approximately $0.00 in transactions. Related Companies BRDG Major Shareholders SAFE Major Shareholders SBR Major Shareholders DEA Major Shareholders CSR Major Shareholders PLYM Major Shareholders FBRT Major Shareholders ORC Major Shareholders UNIT Major Shareholders NXRT Major Shareholders This page (NASDAQ:DMAA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Drugs Made In America Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Drugs Made In America Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access